INTRODUCTION
The treatment of tumors that overexpress HER-2/neu (HER-2) remains a challenge in many therapeutic contexts in the clinic. HER-2 is a transmembrane protein receptor and a potent oncoprotein implicated in cancer initiation and progression. It has been shown that HER-2 is immunogenic as observed by the presence of antibodies and cellular immune responses. 1, 2 However, tumor resistance to Trastuzumab, an anti-HER-2 monoclonal antibody currently used in the clinic, shows that more effective treatments are needed for HER-2-expressing tumors. 3 Gene transfer vectors are promising tools for the prevention and treatment of cancer. 4, 5 Viral vectors provide an efficient way to modify and incorporate exogenous genes, or to perturb the expression of endogenous genes. Adenovirus vectors (AdVs) and lentivirus vectors (LVs) are among the most popular systems for gene delivery. LVs can stably transduce non-dividing cells with long-term expression of the transgene through proviral integration into the target cell genome. 6, 7 Another advantage of the use of LVs is the possibility of modifying the virus' envelope protein, permitting a broader tropism. Moreover, LVs are not inherently immunogenic, and do not elicit immune or inflammatory responses in hosts unless given at very high doses. 8 We have previously shown that injected LVs can circulate in mice in vivo without eliciting a response against the virus itself. 9 Unlike LVs, AdVs do not integrate into the host genome at an appreciable frequency, eliminating the possibility of insertional mutagenesis, and thus are intrinsically safer from an oncogenic perspective. However, AdVs have been shown to induce strong auxiliary immune responses in its hosts.
Direct infection with AdVs or LVs that engineer tumor antigen expression is one way to employ these vectors as cancer vaccines. However, dendritic cells (DCs) are considered the most clinically effective vaccine platforms. Genetically modified DCs have been shown to be more efficient in the induction of a specific antitumor memory T-cell responses relative to peptide loaded DCs. 10 Viral transduction is a useful platform to load DCs with tumor antigens that has advantages over direct virus injections including the ability to deliver repeated vaccinations because virus-specific neutralizing antibodies are avoided and better activation of both tumoricidal CD4+ T cells and NK cells occurs. [11] [12] [13] Although it is known that AdVs and LVs can effectively introduce genes into DCs, there is a paucity of data directly comparing the immunogenicity and systemic consequences of employing these two major vector systems in side-by-side experiments. In this study, we used a murine tumor model to compare the immune response induced by DCs transduced with AdVs and LVs encoding a xenoantigenic form of rHER-2, in order to more effectively break the tolerance to self-antigens. 11, 14 Such a head-to-head comparison points to mechanistic differences and can lead to protocol designs that may favor certain responses over others.
RESULTS

Adenovirus and lentivirus infections do not affect the differentiation and maturation of DCs in vitro
In this study, we engineered both AdVs and LVs encoding the fulllength rHER-2 complementary DNA. Transgene expression was driven by the murine cytomegalovirus promoter in the AdV vector (Figure 1) , while in the LV, expression was regulated by the elongation factor-1a promoter ( Figure 1 ). Corresponding vectors engineering expression of enhanced green fluorescent protein (enGFP) were used as controls.
Owing to the transient nature of AdV-induced transgene expression, bone marrow-derived DCs were infected on day 5 of in vitro culture and injected into recipient animals on day 8. However, LV transductions were performed on day 3 to maximize transduction efficiency and also injected on day 8. Transduced DCs will herein be referred to as rHER-2/DCs and enGFP/DCs, respectively. We determined a similar level of rHER-2 expression on DCs empirically using an multiplicity of infection (MOI) of 100 for AdVs and MOI of 15-20 for LVs. Analysis of rHER-2 expression on the day of vaccination illustrates an infection rate of 50.6% ( ± 4.8%) and 46.9% ( ± 7.4%) for AdV and LV, respectively, using these conditions. Representative data are shown in Figure 2a . Similar results were obtained for enGFP expression; 52.6% ( ± 7.3%) of AdV-transduced DCs were positive for enGFP and 51.8% ( ± 6.4%) of LV-transduced DCs were positive for enGFP expression ( Figure 2a) .
Next, we analyzed whether the AdV and LV transductions would affect the in vitro differentiation and maturation of the DCs. DCs were analyzed before (day 7) and after (day 8) maturation with tumor necrosis factor-a. rHER-2/DCs were typical as noted by their morphology, dendrites (data not shown), and the expression of differential marker CD11c (Figure 2b ). In addition, we observed that neither infection induced the maturation of DCs. rHER-2/DCs maintained an immature phenotype similar to the non-transduced DCs (NT/DCs) with high expression of CD11c, low expression of major histocompatibility complex II, and low expression of costimulatory molecules CD80 and CD86 (Figure 2b ). Maturation was achieved by tumor necrosis factor-a addition; the DCs demonstrated upregulation of major histocompatibility complex II, CD80 and CD86 on their cell surface (Figure 2c) . A similar effect was observed on the enGFP/DCs (data not shown).
Vaccination with both adenovirus-and lentivirus-transduced rHER-2/DCs induces a strong and similar inhibition of tumor growth in mice To investigate possible differences in the gross induction of antitumor immune responses between rHER-2/DCs transduced by AdV and LV, we employed an aggressive RM-1 tumor model overexpressing murine HER-2 (RM-1-mHER-2) as previously described by our group. 13 We chose a small dose of genetically modified DCs to evaluate the intensity of immune response induced by AdV and LV. Groups of C57BL/6 mice were injected subcutaneously with RM-1-mHER-2 tumor cells and the tumors were allowed to grow to a moderate size (B20 mm 3 ) for 4 days before the vaccination. At day 4 post-tumor implantation, the mice were injected in their footpad with 2Â10 5 rHER-2/DCs transduced either with AdV or LV. NT/DCs and enGFP/ DCs were used as controls.
As can be seen in Figure 3 , treatment with both the AdV-and LV-rHER-2/DCs markedly reduced the tumor growth for 2 weeks when compared with the NT/DC-and enGFP/DC-treated groups in three separate experiments. In contrast, tumors from the enGFP/DCtreated groups progressed from day 8 post-tumor injection; by day 14 all mice in these groups developed large (B1400 mm 3 ) and/or ulcerated tumors. Under the same conditions, vaccination with NT/DCs produced similar uncontrolled tumor growth. Interestingly, no significant differences in tumor volume were observed between mice treated with AdV-or LV-transduced DCs.
Immunotherapy with AdV-rHER-2/DCs rather than LV-rHER-2/ DCs results in a higher infiltration of CD4+ and CD8+ T cells Given that AdV-and LV-rHER-2/DCs induced a similar inhibition of tumor development, we sought to determine whether this correlated with similar expansion of CD4+ and CD8+ T-cell subsets. To address this question, splenocytes obtained from vaccinated mice at day 10 post-DC immunization were stained with anti-CD4 and anti-CD8 antibodies and analyzed by flow cytometry. As expected, the frequencies of CD4+ and CD8+ T cells in the spleen were higher in the rHER-2/DC-treated group than in the NT/DC-and enGFP/DC-treated groups (Figure 4a ). However, the most pronounced difference between rHER-2/DC-and enGFP/DC-treated groups was observed in the AdVinfected DCs, in which the differences were 10.7% for CD4+ and 6.5% for CD8+ splenocytes. The increase in the CD4+ and CD8+ T-cell frequencies between LV-rHER-2/DCs and enGFP/DCs were 6.7 and 3.6%, respectively. No differences were noted among the control groups. Interestingly, mice treated with rHER-2/DCs from the AdV transductions had significantly higher expansion of CD4+ and CD8+ T cells in the spleen than the mice that were vaccinated with LV-rHER-2/DCs. The percentages of CD4+ and CD8+ splenocytes in the mice immunized with AdV-rHER-2/DCs vaccine were 25.7% ( ± 1.4%) and 15.3% ( ± 0.8%) respectively, while for LV-rHER-2/DCs the levels were 20.9% (±0.9%) for CD4+ cells and 12.9% (±0.5%) for CD8+ T cells (Figure 4a ).
To further assess whether the observed differences in the spleens between animals administered AdV-and LV-rHER-2/DCs was also reflected at the tumor site, we performed immunohistochemical analysis of the tumors 10 days after DC injection. Sections of tumors were prepared and stained with anti-CD4 and anti-CD8 antibodies and the presence of positively stained cells was evaluated by microscopy. Tumors examined from mice vaccinated with rHER-2/DCs, either transduced with AdVs or LVs, were strongly infiltrated by CD4+ T cells, while the control groups exhibited a small number of positive cells (Figure 4b ). LV-rHER-2/DC therapy induced sixfold (Po0.0010) more CD4+ T-cell infiltration than the control group, whereas AdV-rHER-2/DCs had a threefold increase (Po0.0195) (Figure 4c) . The difference in this measurement was not significant between AdVand LV-DCs. However, the accumulation of CD8+ T cells within the tumor was approximately twofold (Po0.0290) higher in mice that received the AdV-rHER-2/DCs than in animals treated with the DCs transduced with LVs ( Figure 4c ). An increased number of CD8+ T cells was also found in the AdV-rHER-2/DCs vaccinated mice in comparison with their counterpart, enGFP/DC control group (Figure 4c ). In contrast, LV-rHER-2/DCs did not induce a significant infiltration of CD8+ T cells at the tumor site.
The role of DCs driving CD4+ and CD8+ T cells is well known. Owing to our initial finding that AdV-and LV-rHER-2/DCs led to a differential balance of CD4+ and CD8+ T cells, we decided to investigate the DC subsets in the spleen at 10 days after vaccination. Figure 4 Profile of cellular immune responses induced by AdV-and LV-rHER-2/DCs. Tumor-bearing mice vaccinated with either AdV-or LV-rHER-2/DCs, or with the controls DCs (AdV-or LV-enGFP/DCs, and NT/DCs) were killed at day 10 after vaccination. (a) Splenocytes were obtained and immunostained with FITC anti-CD4 and PE anti-CD8 antibodies. The frequency of CD4+ and CD8+ T-cell subsets were determined by flow cytometry. The results represent a mean ( ± s.e.m.) of 15 samples per group from three independent experiments (CD4, *Po0.04; CD8, *Po0.04). (b, c) Tumor tissues were also obtained and processed for immunohistochemical analyses. Tissue sections were incubated with anti-CD4 and anti-CD8 antibodies followed by Alexa Fluor-488 antiIgG secondary antibody and 4,6-diamidino-2-phenylindole (DAPI). Three to five areas of each sample (total of five samples per group) were analyzed using the ImageJ software. The results are shown as mean ( ± s.e.m.). (CD4, *Po0.02, ***Po0.001; CD8, *Po0.02). (d) DCs present in the spleen were stained with anti-CD11c, anti-CD11b, anti-B220, anti-Gr-1 and anti-CD8 antibodies and phenotypically characterized as myeloid (CD11c+CD11b+B220-), plasmacytoid (CD11c+B220+Gr-1+), and lymphoid (CD11c+CD11b-B220-CD8+). For staining of regulatory T cells, splenocytes were incubated with anti-CD4, anti-CD25 and anti-Foxp3 antibodies. Splenocytes were also stained with an anti-NK1.1 antibody. The results are shown as absolute number of cells per spleen. *Po0.0199, **Po0.0076.
DCs were characterized as myeloid (CD11c+CD11b+B220-), plasmacytoid (CD11c+Gr-1+B220+) and lymphoid (CD11c+CD11b-B220-CD8+). Although the absolute number of DC subsets was similar between both therapeutic-DC vaccines, there were differences in the type of DC subsets between the groups when compared with their respective controls. For instance, mice treated with AdV-rHER-2/DCs had significantly more myeloid (B1.6-fold, Po0.0076) and plasmacytoid (B2.6-fold, Po0.0101) DCs than the AdV-enGFP/DC control group, whereas myeloid (B1.9-fold, Po0.0199) DCs were the most significant DC population in the LV-rHER-2/DC group (Figure 4d) .
Regulatory T cells with the CD4+CD25+Foxp3+ phenotype were also evaluated after vaccination. The LV-rHER-2/DC group displayed an Btwofold (Po0.0065) decrease in CD4+CD25+ Treg cell numbers compared to the LV-enGFP/DCs group (Figure 4d ). Although the AdV-rHER-2/DC vaccinated mice had significantly lower frequency of CD4+CD25+ Treg cells in comparison with the AdV-enGFP/DCs group (Po0.0074, data not shown), the absolute number of cells was similar between both groups (Figure 4d ). Furthermore, we did not find any differences in the frequency or absolute number of Tregs at that time point between AdV and LV-DCs immunized mice. Finally, there were no differences observed in the NK1.1+ cell population present in the spleens of mice treated with rHER-2/DCs and that of control DCs (Figure 4d ).
Splenocytes from LV-rHER-2/DC-vaccinated mice strongly respond to RM-1-mHER-2 tumor cells with increased secretion of interferon (IFN)-c by CD4+ T cells Having observed significant differences in the frequency of T-cell infiltration in the spleen and tumor site between animals treated with AdV-and LV-transduced DCs, we were interested in determining the functionality of these splenocytes in vitro. To test this, we evaluated spontaneous cytokine production by total splenocytes from vaccinated mice. As expected, rHER-2/DC therapy induced significantly higher IFN-g expression from splenocytes in comparison with the control groups (Figure 5a ). This finding is consistent with the high frequency of CD4+ and CD8+ T cells in the spleen that probably induced tumor growth inhibition. Comparing both AdV-and LV-rHER-2/DC treatments, the spontaneous secretion of IFN-g was statistically higher in the splenocyte culture from mice receiving AdV-DCs. Indeed, the cytokine concentration in the supernatant from cells derived from mice receiving AdV-rHER-2/DCs was 15.9 ng ml -1 ( ± 2.3 ng ml -1 ), compared with 9.5 ng ml -1 (±0.8 ng ml -1 ) for LV-rHER-2/DCs ( Figure 5a) .
Next, to determine the antitumor specificity of IFN-g-secreting cells, the splenocytes were cultured in the presence of RM-1-mHER-2 tumor cells at the ratio of 1:10 (tumor cells:splenocytes). Splenocytes from the control groups did not react to the tumor cells, maintaining the same level of IFN-g as the non-stimulated cells. Surprisingly, IFN-g production was apparently downregulated when the cells from rHER-2/DC-treated mice were co-cultured with the tumor cells. The concentration of IFN-g dropped from 15.9 to 6.6 ng ml -1 (Po0.0001) for the AdV group and from 9.5 to 5.5 ng ml -1 (Po0.0026) for the LV group (Figure 5a) . In order to see if this effect was reversible, we measured the change in cytokine secretion after increasing the ratio of splenocytes per tumor cell. The IFN-g secretion from the rHER-2/DC group increased significantly in the co-cultures of 1:20 and 1:40 ratios. Splenocytes from the LV-rHER-2/DC mice group strongly responded to tumor cells with 2.5-fold (1:20, Po0.0172) and 4-fold (1:40, Po0.0119) increases in IFN-g secretion, in comparison with the spontaneous level, whereas a 1.5-fold (1:20, Po0.0042) and 2-fold (1:40, Po0.0048) increase was detected in the AdV-rHER-2/DC splenocyte co-culture (Figure 5a) .
We also examined the levels of immunosuppressive cytokines interleukin-10 and transforming growth factor-b in the co-culture of splenocytes and tumor cells. We did not find any differences in interleukin-10 secretion between the rHER-2/DC-and enGFP/DCtreated mice (data not shown). No significant differences were found in the secretion of transforming growth factor-b in the co-culture 1:10 ratio among the animal groups (Figure 5b) . However, the splenocytes from rHER-2/DCs mice co-cultured at the 1:40 ratio produced significantly less transforming growth factor-b than the enGFP/DC group (AdV Po0.0363, LV Po0.0123) (Figure 5b) .
Next, we explored whether IFN-g was produced mainly by CD4+ or CD8+ T cells in each vaccination group. Unfractionated splenocytes from vaccinated mice were co-cultured with RM-1-mHER-2 tumor cells and stained with anti-CD4, anti-CD8, and anti-IFN-g antibodies. Not surprisingly, the number of CD4+IFN-g+ and CD8+IFN-g+ cells in the rHER-2 groups increased significantly after re-stimulation with tumor cells (AdV: CD4+IFN-g+, Po0.0140 and CD8+IFN-g+, Po0.0215; LV: CD4+IFN-g+, Po0.0123), with the exception of the CD8+IFN-g+ cells from the LV group, which did not change in this condition (Figure 5c ). In addition, the IFN-g-producing CD4+ and CD8+ T cells were higher in the rHER-2 groups when compared with enGFP/DCs groups (AdV: CD4+IFN-g+, Po0.0260 and CD8+IFN-g+, Po0.0005; LV: CD4+IFN-g+, Po0.0067 and CD8+IFN-g+, Po0.0206). In this study, IFN-g appeared to be predominantly produced by CD4+ T cells. Notably, when we compared both vector systems, CD4+IFN-g+ T cells were more abundant in the LV-rHER-2/ DC group (Po0.0323), while CD8+IFN-g+ T cells were similar in abundance between the treatments (Figure 5c ).
Higher titer of anti-mHER-2 antibody production following AdV-rHER-2/DC vaccination To further investigate whether AdV-and LV-rHER-2/DCs elicit humoral antigen-specific immunity, sera from immunized mice were tested on cell-based enzyme-linked immunosorbent assay (ELISA) 10 days after the injection of DCs. As a negative control, sera from naive mice were used. RM-1 tumor cells not overexpressing mHER-2 (that is, RM-1-NT) were also used as a control. Corroborating the tumor growth profile, mice that received the rHER-2/DC vaccine developed a significantly higher titer of anti-mHER-2 antibodies (total immunoglobulin G (IgG)) than the control groups (Figure 6a ) at 10 days after immunization. Interestingly, the AdVrHER-2/DCs vaccine generated the highest antibody response titer by ELISA.
Alternatively, we analyzed the binding of serum antibody to RM-1-mHER-2 tumor cells by flow cytometry. Validating the data obtained from the cell-based ELISA, we found that the sera from rHER-2/DCvaccinated mice reacted strongly with the tumor cells in a flow cytometry-based assay, independent of the virus system used to transduce the DCs. The frequency of antibody-RM-1-mHER-2 cell binding increased significantly from day 3 to day 10 in the rHER-2/ DC-treated mice (Figure 6b ). In contrast, the levels of anti-mHER-2 antibody in the sera of mice immunized with NT/DCs and enGFP/ DCs did not change significantly from day 3 to day 10, although the antibody levels were higher in comparison with pre-immunization levels (Figure 6b) . Moreover, the specificity of antitumor antibodies present in the sera of immunized mice was confirmed by incubation with RM-1-NT cells, in which minimal cross-reaction was detected (Figure 6b ). Sera from AdV-rHER-2/DC-immunized mice recognized a 10-fold (Po0.0061) higher frequency of tumor cells than their respective controls, while a 3-fold (Po0.0018) increase was detected between the LV-rHER-2/DC and enGFP/DC groups.
Splenocytes from AdV-and LV-rHER-2/DC-immunized mice elicit antitumor immunity following adoptive transfer into naive tumorbearing mice Having found differences in the magnitude of antitumor immunity generated by vaccination with AdV-and LV-rHER-2/DCs, we next aimed to determine whether tumor-reactive splenocytes from vaccinated mice would provide antitumor immunity in non-DC-vaccinated tumor-bearing mice. Mice at 4 days after tumor implantation received 7.5Â10 6 splenocytes intravenously that were obtained from immunized tumor-bearing donors at 8 days post-vaccination. The frequencies of CD4+ and CD8+ T cells in the donor splenocytes were 23.6 and 14.5% for AdV-rHER-2/DCs, 20.3 and 15.1% for LV-rHER-2/DCs, 12.2 and 9.3% for AdV-enGFP/DCs, 11.2 and 7.5% for LV-enGFP/DCs, and 9.2 and 6.9% for NT/DCs, respectively (Figure 7a ). Adoptive transfer of rHER-2-programmed splenocytes into tumorbearing mice led to statistically significant tumor inhibition. At 14 days post-splenocyte transfer, the tumor volume of the AdV-and LV-rHER-2 group was fivefold smaller than the control groups (Figure 7b ). We did not detect any significant differences between mice treated with splenocytes derived from AdV-or LV-rHER-2/ DC-immunized mice.
DISCUSSION
Overexpression of HER-2 is a common occurrence in a variety of human tumors and often correlates with poor prognosis. Considerable efforts have been made to find a treatment for HER-2-positive tumors using gene therapy. The selection of the virus platform to implement DC vaccination has traditionally been a dilemma. We questioned whether suboptimal results from some AdV-and LV-based antitumor immunotherapy experiments stem from the choice of the virus gene delivery system, where a particular tumor-associated antigen may work better in one virus system than another. To our knowledge, there are no direct reports comparing AdV-and LV-transduced DCs expressing the same antigen. Here, we performed a comparative analysis of DCs overexpressing rHER-2 after AdV and LV infections. We observed that the infection either by AdV or LV did not induce the maturation of DCs. Contrary to some reports, we did not observe maturation of immature DCs following AdV infections. [15] [16] [17] Various other reports support our finding that the AdV itself does not induce DC maturation. [18] [19] [20] These contradictions may be related to differences in virus preparations and infection protocols, such as the number of virus particles per cell (MOI) used or even different lots of fetal calf serum used in the activating cultures. Importantly, in our model, AdV and LV infection of immature DCs did not impair maturation following tumor necrosis factor-a stimulation.
LV vectors are well known for stable and long-lasting expression of transgenes. When we evaluated tumor volumes in animals treated with AdV-and LV-rHER-2/DCs, we found a similar and effective inhibition of tumor growth in both groups. Although AdV transductions result in a non-stable expression of transgenes in comparison with LV transductions, it may not be as relevant in the context of ex vivodirected DC transductions. Fully differentiated mature DCs do not divide and have a short lifespan that varies from 2 to 9 days once they enter the lymph nodes. 21 We presume that neither AdV nor LV infection would alter the longevity of DCs. Moreover, the maturation status and rHER-2 levels on the cell surface were similar between cells infected with both virus systems, suggesting that both cells had the same potential with respect to the expression of co-stimulatory molecules required to sufficiently activate T cells in vivo.
The outcome of tumor growth was similar between animals receiving AdV-and LV-rHER-2/DCs. That said, the magnitude of the immune response mechanism was different. AdV-rHER-2/ DC-treated mice mounted a local and systemic immune response with high frequencies of CD4+ and CD8+ T cells while spontaneous IFN-g secretion was higher than animals treated with LV-rHER-2/ DCs. A previous study using AdVs engineering expression of rHER-2 showed that tumor protection was completely dependent on anti-HER-2 antibody production with participation of CD4+ T cells in the early phase of immunization, but it does not depend on CD8+ T cells. 22 Our results are in agreement with the idea that the generation of anti-HER-2 antibody is important for the development of an efficient antitumor response. Both AdV-and LV-rHER-2/DCs were able to elicit a humoral immune response in comparison with control groups. Contrary to this previous report, in the AdV-rHER-2/ DC model the antitumor immunity appears to involve both CD4+ and CD8+ T cells, whereas for LV-rHER-2/DCs, responses were more related to CD4+ T cells as observed by T-cell infiltration at the tumor site. Other studies have also shown that tumor-specific CD4+ T cells have more potential to eradicate tumors than do CD8+ T cells. 23, 24 On the other hand, our findings demonstrate that splenocytes from LV-rHER-2/DC-immunized mice responded more robustly to RM-1-mHER-2 tumor cells with enhanced secretion of IFN-g by CD4+ T cells in contrast to splenocytes derived from mice that received the AdV-rHER-2/DCs. Moreover, the IFN-g levels induced by AdV vaccines appeared to be dependent on both CD4+ and CD8+ T cells.
Another difference between AdV-and LV-rHER-2/DC vaccines was observed in our study regarding the subsets of DCs found in the spleen. It is known that different subsets of DCs promote a distinct pattern of cytokines and T-cell stimulation. 25 Here, myeloid and plasmacytoid DCs were found to be predominant in the AdVrHER-2/DC group while the LV counterpart was mainly represented by the plasmacytoid DC subset. Despite the involvement of plasmacytoid DCs with infection immune responses, 26, 27 data in the literature also support the direct or indirect antitumor effect of this specific DC subset. 28 A synergistic effect of myeloid and plasmacytoid DCs inducing specific antitumor immune response has also been discussed before. 29, 30 The combination of both subsets enhanced the frequency of antigen-specific CD8+ T cells and antitumor immunity. Consistent with these findings, our results with AdV showed an antitumor effect that suggest a main role of CD8+ T cells or a balance of CD4+/CD8+ T cells.
We suggest that the differences observed may be related to an altered repertoire of immunodominant epitopes presented by the transduced DCs. One vaccine may narrow the immune response toward a limited number of immunodominant epitopes while the other goes against a subdominant repertoire. This is supported by a recent publication from Dai et al. 31 involving directly administered boosting immunizations using LV-gag and AdV-gag. Here, the authors suggested that the LVs may direct DCs to load and present antigens more efficiently in this context.
We also hypothesize that the enhanced frequency of CD4+ and CD8+ T cells in the AdV-DCs immunization may be due to the additional anti-viral response that would be seen with this vaccine schema, which would not be present with the LV-DCs. This is supported by findings that AdV-transduced DCs are also loaded with viral capsid antigens 32 and can stimulate an anti-viral response. Regardless of the differences in anti-vector responses, the overall antitumor activity was the same between both vectors. Taken together, our results indicate that AdV-and LV-mediated xenoantigen rHER-2 can be expressed at similarly high levels in DCs, which in turn, can activate antigen-specific cellular and humoral immune responses. Although the transient expression of foreign antigens may not be a concern in cancer gene therapy, the virus system seems to have an impact on determining the nature of the immune responses. Future studies may seek to capitalize on this to direct particular responses.
MATERIALS AND METHODS
Cell lines and mice
RM-1 prostate tumor cells, syngeneic to the C57BL/6 strain, were previously engineered to overexpress a kinase-truncated form of murine HER-2/neu (mHER-2). 13 Cells were cultured in Dulbecco's modified Eagle's medium (Sigma Aldrich, St Louis, MO, USA) media supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA) and maintained at 37 1C at 5% CO 2 ; passages were performed every 2 days. C57BL/6 mice were bred and housed under specific pathogen-free conditions at the University Health Network Animal Resource Centre. Animal experimentation followed protocols approved by the UHN Animal Care Committee (ACC).
Vector construction and virus production
A kinase-inactivated rat HER-2 AdV was previously constructed and generously provided by Dr Y Wan. 11 Importantly, a single amino acid replacement (lysine to alanine) at codon 758 was performed to inactivate the kinase domain. Construction of the rat HER-2 LV was performed by subcloning of the rat HER-2 complementary DNA into the pCCL LV transfer vector backbone kindly provided by Dr L Naldini. 33 Briefly, the enGFP and delta Low-affinity Nerve Growth Factor Receptor dual-promoter system cassette in the pCCL vector was removed by digestion and the elongation factor-1a promoter subcloned into ClaI and AscI restriction enzyme sites. Subsequently, the full-length rHER-2 was amplified from the pJ4 Neu N plasmid by PCR using the KOD Hot Start DNA polymerase (EMD4Biosciences, San Diego, CA, USA). The rHER-2 complementary DNA fragment of approximately 3.7 kb in size was subsequently subcloned downstream the elongation factor-1a promoter into AscI and SalI restriction enzyme sites to yield the plasmid pCCL.SIN.cPPT.EFIa.rHER2-neu.Wpre. The final construction was verified by bidirectional DNA sequencing.
Recombinant rHER and enGFP AdV (denoted as AdV-rHER-2 and AdVenGFP) were generated by the co-transfection of the rat HER Ad5 shuttle vector with the rescue vector pBHG10 into HEK 293 cells as previously described. 11 All recombinant Ad vectors were propagated using 293 cells and purified using CsCl gradient centrifugation as described previously. 34 Recombinant rHER-2 and enGFP LVs (denoted as LV-rHER-2 and LV-enGFP) were produced by transient co-transfection of HEK 293T cells with three plasmids: pMD.G (VSV-g envelope), pCMVD8.91 (packaging) and either rHER-2 or enGFP lenti-transfer vectors. 6, 35 Transfections were performed using branched polyethylenimine as previously described. 36 Viral supernatants were harvested 48 and 72 h after transfection and concentrated by ultracentrifugation at 50 000 g. The final concentrated virus was stored at À80 1C until use. Functional viral titers were determined by serially diluted transductions of HEK 293 T cells, followed by rHER-2 expression analysis using flow cytometry.
DCs generation and infection
To generate DCs, murine bone marrow cells were cultured in RPMI-1640 medium (Sigma Aldrich) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 5% non-essential amino acids (Gibco, Carlsbad, CA, USA), 100 U ml -1 penicillin, and 100 mg ml -1 streptomycin (complete medium). Briefly, bone marrow was flushed from the femurs and tibias of C57BL/6 mice and bone marrow cells were plated in Petri dishes in complete medium, which was further supplemented with 50 ng ml -1 recombinant murine granulocyte-macrophage colony-stimulating factor (Peprotech, Rocky Hill, NJ, USA). DCs were transduced on day 3 with LVs at MOI of 15-20 and on day 5 with AdVs at MOI of 100. On day 7 of culture, DC maturation was induced by the addition of 100 ng ml -1 tumor necrosis factor-a (Peprotech) for 24 h. The following day, non-adherent and loosely adherent cells were harvested by gentle pipetting, washed, and resuspended in phosphate-buffered saline (PBS) for injection. Mice were immunized with matured DCs on day 8 of culture.
Tumor inoculation and immunization
C57BL/6 mice were injected subcutaneously on the dorsal region with 2Â10 5 RM-1-mHER-2 tumor cells in PBS. On day 4 when the tumors reached approximately 20 mm 3 in volume, the mice were immunized in the footpad with 2Â10 5 rHER-2/DCs transduced by either AdV or LV. NT/DCs or enGFP/ DCs were used as controls. Mice were observed every other day and the length (l), width (w) and height (h) of each tumor was measured using a digital caliper. Tumor volume was calculated using the formula lÂwÂh. Mice were euthanized when tumors ulcerated or surpassed 1500 mm 3 in volume (as required by the UHN ACC).
Adoptive transfer of splenocytes
Eight days after immunization with DCs, spleens were harvested and homogenized to single-cell suspensions. Unfractionated splenocytes were depleted of red blood cells and resuspended in PBS for injection. Four days after tumor implantation, tumor-bearing mice received 7.5Â10 6 splenocytes intravenously. Tumor growth was monitored every 2 days with calipers and measurements were expressed as tumor volume as above.
Flow cytometry analysis
